NASDAQ$PGEN
Precigen Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Precigen reported first quarter financial results, achieved progress in streamlining healthcare operations and reducing operating costs.
Precigen reported total revenues of $29.8 million and a net loss from continuing operations attributable to Precigen of $29.9 million, or $(0.19) per basic share. Cash, cash equivalents, and short-term investments totaled $149.2 million at March 31, 2020.
- Received FDA clearance of PRGN-2009 to initiate a Phase 1/2 trial in HPV-positive solid tumors.
- Dosing in the second dose level of the intraperitoneal (IP) arm of the Phase 1 trial of PRGN-3005 UltraCAR-T was completed.
- Enrollment of patients in the non-lymphodepletion and lymphodepletion arms of the Phase 1 trial of PRGN-3006 UltraCAR-T has been unaffected by the COVID-19 pandemic to date.
- MBP Titan LLC significantly reduced its resource requirements through a workforce reduction.
Headline financials
Revenue & EPS history
Precigen · Revenue · Quarterly
$29.8M
Revenue by segment
Precigen · $19.1M total across 3 segments · Q1 2020
- Service revenue$13.9M—73.0%
- Product revenue$4.96M—26.0%
- Collab & licensing$210K—1.1%
Forward guidance
Precigen maintains guidance for clinical readouts in 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2020
+0.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+1.4%
Avg return
30 days after
50%
26 / 52 earnings
Positive
+31.0%
Q2 2023
Best reaction
-38.9%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +1.7% | -0.2% | — | |
| Q3 2025 | +25.6% | +9.3% | -4.4% | |
| Q2 2025 | +6.1% | +63.9% | +110.6% | |
| Q1 2025 | -2.8% | -5.7% | +0.7% | |
| Q4 2024 | +0.6% | -4.5% | -22.3% | |
| Q3 2024 | -10.4% | -13.0% | -26.1% | |
| Q1 2024 | +6.7% | +2.2% | +25.9% | |
| Q4 2023 | +3.6% | +0.7% | -5.0% | |
| Q3 2023 | -13.5% | -19.8% | -6.3% | |
| Q2 2023 | +31.0% | +43.1% | +39.7% | |
| Q1 2023 | -9.5% | -4.0% | -6.3% | |
| Q4 2022 | +16.4% | -6.0% | -15.5% | |
| Q3 2022 | +11.2% | +18.1% | -2.5% | |
| Q2 2022 | +11.6% | +14.5% | +11.1% | |
| Q1 2022 | +3.2% | +8.0% | +23.2% | |
| Q4 2021 | -1.3% | -10.2% | -6.2% | |
| Q3 2021 | -7.1% | -11.8% | -33.3% | |
| Q2 2021 | +8.6% | +10.4% | +10.6% | |
| Q1 2021 | -0.2% | +5.7% | +9.5% | |
| Q4 2020 | +1.7% | +0.1% | -18.4% | |
| Q3 2020 | +22.2% | +20.4% | +69.7% | |
| Q2 2020 | -5.7% | -8.8% | -1.0% | |
| Q1 2020 | -5.9% | -4.2% | -4.7% | |
| Q4 2019 | -14.5% | -19.0% | -27.4% | |
| Q3 2019 | -1.1% | +2.0% | +6.3% | |
| Q2 2019 | -7.2% | -10.3% | -23.4% | |
| Q1 2019 | -1.1% | +0.7% | +22.2% | |
| Q4 2018 | -38.9% | -39.4% | -36.5% | |
| Q3 2018 | -19.3% | -24.4% | -32.1% | |
| Q2 2018 | -5.7% | -4.6% | -2.9% | |
| Q1 2018 | -19.5% | -13.0% | -9.3% | |
| Q4 2017 | +23.6% | +20.9% | +17.7% | |
| Q3 2017 | -25.3% | -19.7% | -15.9% | |
| Q2 2017 | -5.2% | -4.0% | -15.0% | |
| Q1 2017 | +21.5% | +32.0% | +15.0% | |
| Q4 2016 | +5.8% | +2.1% | -11.0% | |
| Q3 2016 | +14.1% | +24.0% | +15.7% | |
| Q2 2016 | +3.3% | +4.5% | +0.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.8% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | +17.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | -2.9% | — | — | |
| Q1 2013 | +2.9% | — | — | |
| Q1 2014 | -11.7% | — | — | |
| Q4 2013 | +5.5% | — | — | |
| Q3 2012 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | -7.8% | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro